You are here

Spark Therapeutics

Is biopharma’s first $1.5M therapy now in Phase III?

Is biopharma’s first $1.5M therapy now in Phase III?

Endpoints

Spark Therapeutics

Flag link:

Sparks sells regulatory fast pass to Jazz for $110M

Sparks sells regulatory fast pass to Jazz for $110M

Biopharma Dive

Spark Therapeutics

Jazz Pharmaceuticals

priority review vouchers

Flag link:

‘That’s $425,000 right there’ — the anxious launch of a gene therapy with a record sticker price

‘That’s $425,000 right there’ — the anxious launch of a gene therapy with a record sticker price

Stat

Spark Therapeutics

Flag link:

Spark lays groundwork for US Luxturna launch

Spark lays groundwork for US Luxturna launch

Biopharma Dive

Spark Therapeutics

Flag link:

Cost over sight? Spark's blindness cure has the industry talking

Cost over sight? Spark's blindness cure has the industry talking

Medical Marketing and Media

Spark Therapeutics

Flag link:

Novartis move signals further gene therapy resurgence

Novartis move signals further gene therapy resurgence

EP Vantage

Spark Therapeutics

Flag link:

Spark licenses blindness gene therapy rights outside U.S. to Novartis

Spark licenses blindness gene therapy rights outside U.S. to Novartis

Yahoo/Reuters

Spark Therapeutics

Flag link:

Three Interviews From the J.P. Morgan Healthcare Conference

Three Interviews From the J.P. Morgan Healthcare Conference

Motley Fool

Arena Pharmaceuticals

Spark Therapeutics

Flag link:

Drugmakers see a pricing blueprint in an $850,000 gene therapy

Drugmakers see a pricing blueprint in an $850,000 gene therapy

Reuters

Spark Therapeutics

Flag link:

Spark prices its gene therapy as most expensive U.S. medicine — but with plans to ease cost concerns

Spark prices its gene therapy as most expensive U.S. medicine — but with plans to ease cost concerns

Stat

Spark Therapeutics

Flag link:

FDA rolls out an early and historic OK for Spark’s pioneering gene therapy

FDA rolls out an early and historic OK for Spark’s pioneering gene therapy

Endpoints

Spark Therapeutics

retinal dystrophies

Flag link:

8 Takeout targets to watch in 2018

8 Takeout targets to watch in 2018

BioPharma Dive

Bristol-Myers Squibb

Madrigal Pharmaceuticals

Spark Therapeutics

Flag link:

[video]ASH 2017 Recap: These Were the Big Winners and Losers

[video]ASH 2017 Recap: These Were the Big Winners and Losers

Motley Fool

Juno Therapeutics

Spark Therapeutics

Flag link:

ASH 2017: What you missed

ASH 2017: What you missed

BioPharma Dive

Spark Therapeutics

Gilead Sciences

Juno Therapeutics

Flag link:

ASH17: Spark gene therapy falls behind BioMarin in hemophilia

ASH17: Spark gene therapy falls behind BioMarin in hemophilia

BioPharma Dive

Spark Therapeutics

Flag link:

Spark, Pfizer pass another milestone with impressive results treating hemophilia B

Spark, Pfizer pass another milestone with impressive results treating hemophilia B

Endpoints

Spark Therapeutics

Flag link:

How much is your vision worth? Spark CEO Jeff Marrazzo has a price in mind

How much is your vision worth? Spark CEO Jeff Marrazzo has a price in mind

Endpoints

Spark Therapeutics

RPE65-mediated retinal dystrophy

Flag link:

Reader poll: Pfizer most likely buyer for Spark

Reader poll: Pfizer most likely buyer for Spark

Biopharma Dive

Spark Therapeutics

Flag link:

We may soon have our first $1 million drug. Who will pay for it? And how?

We may soon have our first $1 million drug. Who will pay for it? And how?

Stat

Spark Therapeutics

Flag link:

Pages